Albumedix range of recombinant human albumins (the Recombumin® product portfolio) can be used across a range of application areas. Learn more about each here.

The cell and gene therapy industry has, over the past years, proven its potential and many patients are now benefitting from advanced therapies with dramatic clinical results. Increasing clinical activity in diverse and more prevalent indications is prompting considerable effort and progress in addressing various manufacturing and logistical challenges in order to make more practical and scalable therapies.

One of our valued medical device partners in the UK, Chalice Medical, is working around the clock to handle the huge surge in demand of their ECMO devices (oxygenators / life support machines). This surge has come as a result of the Covid-19 pandemic. In response, Albumedix is doing all we can to prioritize their shipments and any others related to the outbreak of the virus.

Albumedix, the world leader in recombinant human albumin, announced today that the Center for Biologics Evaluation and Research (CBER), one of six main centers for the U.S. Food and Drug Administration (FDA), has accepted a Drug Master File (DMF) submission for the company’s Recombumin® Elite.

As a global provider of recombinant human albumin for the life science industry, Albumedix are fully dedicated to ensuring a stable product supply to our customers in all regions of the world. As such, we are actively monitoring and responding to the potential impact of the Coronavirus disease (COVID-19) outbreak.

Albumedix is a world leading manufacturer of recombinant human albumin (rHA), and as such our manufacturing plant is the core of our business. As a company, we talk a lot about our rHA products, how they’re useful in different applications and what benefits they can bring to final therapies for patients worldwide. However, we don’t talk as much about the amazing people within our business that make the magic happen.

As a key excipient/raw material supplier, Albumedix monitors advancements, innovation, trends and conversations in the cell therapy manufacturing industry closely. This is why at the end of February, our Director of Market Development and Communication (Poula Maltha Krogh) attended the Cell Therapy Manufacturing ASIA conference in Kyoto.

Albumedix attended the International Pharmaceutical Excipients Council (IPEC) Annual Forum and AGM in Aix-en-Provence, France earlier this month.

Back from Phacilitate conference in Miami, we reflect on the exciting trends and developments presented and cannot wait for what 2020 will bring!

Albumedix has attended PepTalk for many years, and as the world of biopharmaceuticals expands towards more complex entities, albumin will always play a role in the stabilisation of the most challenging APIs. As an example of albumin’s potential in stabilising difficult biopharmaceuticals, we have presented the results obtained for glucagon , a notoriously insoluble and unstable peptide. Albumin was not only able to allow the solubilisation of this APIs in a close-to-physiological conditions, where the peptide is insoluble, but also protected it from chemical and physical degradation in accelerated stability tests.

In December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new, four-storey manufacturing plant extension being confirmed as watertight!